Tetrahydrobiopterin is a limiting factor of nitric oxide generation in interleukin lfl-stimulated rat glomerular mesangial cells. Treatment of mesangial cells with recombinant human interleukin 113 triggers the expression of a macrophage-type of nitric oxide (NO) synthase and the subsequent increase of cellular concentration of cOMP and nitrite production. Tetrahydrobiopterin (BH4) is an essential cofactor for NO synthase, and in the present study we investigated its impact on inducible NO synthesis in mesangial cells. Inhibition of GTP-cyclohydrolase I, the rate-limiting enzyme for BH4 synthesis, with 2,4-diamino-6-hydroxy-pyrimidine (DAHP) potently suppresses IL-1f3-induced nitrite production and elevation of cellular cOMP levels. This inhibitory effect of DAHP is reversed by sepiapterin, which provides BH4 via the pterin salvage pathway. Most importantly, sepiapterin dose-dependently augments IL-113-stimulated NO synthesis, indicating that the availability of BH4 limits the production of NO in cytokine-induced mesangial cells. N-acetylserotonin, an inhibitor of the BH4 synthetic enzyme sepiapterin reductase, completely abolishes IL-1fi-stimulated nitrite production, whereas methotrexate, which inhibits the pterin salvage pathway, displays only a moderate inhibitory effect, thus suggesting that mesangial cells predominantly synthesize BH4 by de novo synthesis from G1'P. In conclusion, these data demonstrate that BH4 synthesis is an absolute requirement for, and limits IL-1f3 induction of NO synthesis in mesangial cells. Inhibition of BH4 synthesis may provide new therapeutic approaches to the treatment of pathological conditions involving increased NO formation.
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The synthesis of NO from L-arginine by NO synthase is an important intracellular and intercellular signalling pathway originally discovered in macrophages and endothelial cells [1, 2] .
Molecular cloning and sequence analyses revealed the existence of at least three main types of NO synthase isoforms. The brain and endothelial enzymes are constitutively expressed and are 60% identical at the amino acid level. Both enzymes are regulated by Ca2-mobi1izing agonists that trigger an increase in intracellular free Ca2, which binds to calmodulin, and thus activates NO synthase [1, 2] . A third type of NO synthase has been cloned from murine macrophages and proved to be 51% and 50% homologous to the brain and endothelial enzymes, respectively [3, 4] . The macrophage-type of NO synthase is not constitutively expressed, but is induced by y-interferon and lipopolysaccharide, and is Ca2-independent. The macrophage NO synthase is regulated on a transcriptional level and once induced is active for hours and days. Not surprisingly, therefore, the inducible macrophage enReceived for publication April 20, 1994 and in revised form June 3, 1994 Accepted for publication June 6, 1994 © 1994 by the International Society of Nephrology zyme produces amounts of NO that are several hundred times higher than the ones produced by the constitutive endothelial cell and brain enzymes which are only active during the short periods of elevated intracellular Ca2 observed after exposure of cells to Ca2-mobilizing agonists [1, 2] .
Glomerular mesangial cells are a specialized type of vascular smooth muscle, so-called pericytes, which take part in the regulation of the glomerular filtration rate [5, 6] . These cells respond to endothelial-derived NO with increased levels of intracellular cGMP and subsequent relaxation [7, 8] . In addition, mesangial cells synthesize several inflammatory mediators such as growth factors and cytokines and actively participate in the pathogenesis of inflammatory glomerular injury [9, 10] . We and others have shown that cytokines, such as IL-i and tumor necrosis factor a, or lipopolysaccharide induce a NO synthase in mesangial cells with subsequent elevation of cellular cGMP concentrations [11] [12] [13] . The excessive formation of NO and cGMP in mesangial cells not only alters contractile responses of the cells [14] , but may also cause tissue injury and thus contribute to the pathogenesis of certain forms of glomerulonephritis [15, 16] . As in smooth muscle cells [17] the NO synthase expressed in mesangial cells in response to cytokine stimulation resembles the macrophage-type enzyme [14] . NO synthase is completely dependent on the presence of L-arginine and NADPH, is weakly enhanced by exogenous BH4 and is not significantly affected by Ca2 and calmodulin [14] .
When mesangial cell NO synthase is partially purified by affinity chromatography on ADP-agarose to remove the endogenous BH4, the purified enzyme depends to 70% on addition of this compound [14] . Moreover, IL-1j3 and tumor necrosis factor a markedly increase the mRNA levels of the inducible macrophage form of NO synthase in mesangial cells, whereas control cells, not exposed to cytokines, do not display detectable levels of NO synthase mRNA [18] .
Biosynthesis of BH4 occurs via two distinct pathways: a de novo pathway which uses GTP as a substrate and a salvage pathway using the intracellular pool of pre-existing dihydropterins as depicted in Figure 1 [19, 20] . Cytokines like y-interferon or tumor necrosis factor a have been reported to potently stimulate the de novo synthesis of BH4 in human and murine macrophages, fibroblasts and endothelial cells [20] . This increased production of BH4 may be required in order to ensure a sufficient supply of cofactor for long-term synthesis of NO via the inducible macrophage-type NO synthase [21] .
The present paper addresses the impact of BH4 supply in by the sequential action of sepiapterin reductase and dihydrofolate reductase. H2NTP, dihydroneopterin triphosphate; 6PPH4, 6-pyruvoyltetrahydropterin; BH4; tetrahydrobiopterin; DAHP, 2,4-diamino-6-hydroxypyrimidine; NAS, N-acetylserotonin; MTX, methotrexate.
cytokine-stimulated giomerular mesangial cells. We provide evidence that the endogenous synthesis of BH4 limits the synthesis of NO in mesangial cells exposed to IL-lp. Pharmacological modulation of endogenous BH4 levels may provide new therapeutic approaches for the treatment of inflammatory reactions associated with high NO output. Part of this material was presented in abstract form at the 25th Annual Meeting of the Swiss Societies of Experimental Biology in Bern [22] .
Methods

Cell culture
Rat glomerular mesangial cells were cultured as described previously [23] . In a second step, single cells were cloned by limited dilution using 96-micro-well plates. Clones with apparent mesangial cell morphology were used for further processing. The cells exhibited the typical stellate morphology. Moreover, there was positive staining for the intermediate filaments desmin and vimentin, which are considered to be specific for myogenic cells, positive staining for Thy 1.1 antigen, negative staining for factor Vill-related antigen and cytokeratin excluded endothelial and epithelial contaminations, respectively. The generation of inositol trisphosphate upon activation of the angiotensin II AT1 receptor was used as a functional criterion for characterizing the cloned cell line [24] . The cells were grown in RPMI 1640 supplemented with 10% fetal calf serum, penicillin (100 U/mi), streptomycin (100 g/ml) and bovine insulin at 0.66 U/ml (Sigma). For the experiments passages 8 to 15 were used. Confluent mesangial cells in 24-well plates (16 mm diameter wells) were incubated with the indicated concentrations of compounds in Dulbecco's modified Eagle's medium (DMEM) without phenol red containing 0.1 mg/mI of bovine serum albumin for 24 hours. Thereafter, the medium was removed for determination of nitrite concentration.
Cell protein determination was performed according to the method of Lowry et al [25] with bovine serum albumin (Sigma) as standard.
Nitrite analysis
Nitrite production by rat glomerular mesangial cells was measured by the Griess reaction as described previously [26] . After stimulation the medium was withdrawn and centrifuged for 10 minutes at 6000 rpm in an Eppendorf-iab centrifuge. Nitrite was measured by mixing 150 j.tl of the supematant with an equal volume of Griess reagent. The absorbance at 550 mm was measured and the nitrite concentration was determined using a calibration curve with sodium nitrite standards. 
Results
Incubation of mesangial cells for 24 hours with IL-113 (2 nM) stimulates the synthesis of nitrite ( Fig. 2A) , a stable end product of cellular NO formation, and increases the concentration of intracellular cGMP (Fig. 2B) , well in agreement with previous studies [ii, 14, 18] . To address the requirement for BH4 in the IL-1/3-stimulated NO production, we incubated mesangial cells with DAHP, a competitive inhibitor of GTP cyelohydrolase I, the rate-limiting enzyme in the biosynthetic pathway of BH4 (Fig. 1) [27]. We found that treatment of mesangial cells with DAHP dose-dependently prevented IL-1fl-induced nitrite production ( Fig. 2A) as well as cGMP elevations (Fig. 2B) . Half-maximal inhibition of IL-1/3-stimulated nitrite and cGMP formation are observed at 0.49 m and 0.48 mivi DAHP, respectively. DAHP has no effect on sodium nitroprusside-stimulated guanylate cyclase activity (data not shown), thus suggesting that the compound affects NO synthesis rather than cOMP formation itself. Addition of sepiapterin (100 jxM), which is intracellularly converted into BH4 via the dihydrofolate reductase-dependent pterin salvage pathway as depicted in Figure 1 [19, 20] , completely reverses the inhibitory action of DAHP on nitrite production, as shown in Figure 3 . Inhibition by DAHP is not overcome by uneonjugated pteridines such as pterin-6-carbocylic acid and isoxanthopterin, which cannot be converted to BH4 [19] (data not shown). In the absence of DAHP, sepiapterin potentiates the IL-l(3-stimulated nitrite production as shown in Figure 3 . At a concentration of 100 .tM, sepiapterin augmented cytokine-induced nitrite generation by more than threefold (Fig. 3) . Another inhibitor that blocks BH4 biosynthesis in cells is N-acetylserotonin which selectively inhibits sepiapterin reductase (Fig. 1) [28] . N-acetylserotonin has been used to deplete cellular levels of BH4 in several systems [28] [29] [30] . As shown in Figure 4 , N-acetylserotonin concentration-dependently suppresses IL-1/3-stimulated nitrite production in mesangial cells. Half maximal inhibition is observed at 0.25 mrvi N-acetylserotonin. Finally, we examined the effects of methotrexate which interferes with BH4 synthesis via the salvage pathway by specifically blocking dihydrofolate reductase (Fig. 1) [19] . Methotrexate only slightly attenuates IL-i (3-stimulated nitrite production to a maximal extent of approximately 30% (Fig. 5) . As compared with untreated control cells, a 24 hour treatment of mesangial cells with 100 MM sepiapterin, 5 mM DA}IP, 5 mivi N-acetylserotonin, 10 gM methotrexate, 2 n IL-1/3 or combinations of the different agents does not affect cell viability as determined with a sensitive dye-uptake assay [31] .
Discussion
In activated macrophages y-interferon and lipopolysaccharide trigger the expression of an inducible type of NO synthase which produces high amounts of the unstable and extremely reactive gas NO. NO is suggested to account, at least in part, for the killing of bacteria, protozoa, fungi and tumor cells by activated macrophages [1] . We have demonstrated that inflammatory cytokines such as IL-i$ or tumor necrosis factor a induce the expression of a Ca2-independent macrophage-type of NO synthase in rat glomerular mesangial cells that produces tremendous amount of NO [14, 18] . It seems quite possible that the excessive production of NO may provide mesangial cells with properties that make them partially act as macrophages and thus contribute to tissue injury observed in certain forms of glomerulonephritis [15, 16] . This hypothesis gains support from recent observations showing that anti-inflammatory steroids [11, 32] , transforming growth factors of the 13-type [12, 23] , platelet-derived growth factor [33] and the immunosuppressive drug cyclosporin A [18] potently suppress cytokine-induced NO synthase expression in mesangial cells. The inhibition of cytokine induction of NO synthase may be one aspect of the beneficial action of glucocorticoids and cyclosporin A seen in certain renal diseases.
Moreover, at the same time, NO causes relaxation of the contractile mesangial cells [7, 14] and thus leads to a state of glomerular hyperifitration. This condition seems to be an important pathogenetic mechanism for the development of glomerular sclerosis. Cattell et al [34] and Cook and Sullivan [35] have shown that glomeruli isolated from rats with experimental nephrotoxic nephritis or in situ immune complex glomerulonephritis produce nitrite. This synthesis of nitrite was spontaneous and further increased by treatment with lipopolysaccharide. Dexamethasone potently suppressed nitrite production in endotoxin-treated gbmeruli. Furthermore, nitrite generation was also observed in glomeruli isolated from rats with active Heymann nephritis, a model of membranous glomerulonephritis [36] , and in the Thy 1.1 model of mesangial proliferative glomerulonephritis [37] . These data suggest that in several models of experimental glomerulonephritis the formation of NO is increased to micromolar levels, due to the induction of a macrophage-type of NO synthase in infiltrating macrophages as well as in resident mesangial cells. Furthermore, glomerular NO production has been implicated in the pathomechanisms of proteinuria, thrombosis, leukocyte infiltration, matrix production, mesangial cell proliferation and local immunosuppressive effects [15, 16] . Recently Weinberg et al [38] reported that oral administration of NGmonomethylLarginine, a NO synthase inhibitor, prevented the development of glomerulonephritis and reduced the intensity of inflammatory arthritis in MRL-lpr/lpr mice that develop a spontaneous autoimmune disease [39] . It is tempting to suggest that the regional or systemic use of compounds that block the production of NO may be of value in therapy of autoimmune and other inflammatory diseases. This could be achieved by direct inhibitors of NO synthase such as NGmonomethylLarginine or by agents that inhibit the action of NO such as hemoglobin or myoglobin that scavenge free NO [1, 2] . However, these compounds will affect constitutive and inducible NO synthases equally well and thus may lead to unwanted side effects. In an alternative approach we have addressed in the present report the role of the NO synthase cofactor BH4. BH4 is the required cofactor for phenylalanine, tyrosine and tryptophan hydroxylases and alkylglycerol monooxygenase [19] . Besides these enzymes the cofactor role of BH4 is restricted to NO synthase and, therefore, inhibition of BH4 synthesis will result in a very restricted pattern of effects. Our results strongly suggest that synthesis of BH4 is an essential requirement for induction of NO synthase activity in mesangial cells. Inhibition of GTP cycbohydrolase I or sepiapterin reductase by DAHP or N-acetylserotonin, respectively, potently prevents IL-113 induction of NO synthase activity (Figs. 2 and 4) . From these data it seems reasonable to consider inhibitors of biopterin synthesis as a new pharmacological approach applicable to conditions of pathological NO overproduction. In general, sepiapterin reductase inhibition will produce a more specific depletion of BH4 than would inhibition of earlier reactions in the biosynthetic pathway of BH4. The therapeutic potential of BH4 synthesis inhibitors seems to be quite promising as DAHP cannot pass the blood/brain barrier and, therefore, does not interfere with the production of dopamine and serotonin in the central nervous system [40] . Although inhibition of BH4 synthesis does not produce acute inhibitory effects on the constitutive endothelial cell NO synthase, chronic treatment with DAHP has recently been shown to inhibit endothelial NO production [41] . However, considering the enormous requirement of BH4 during cytokine induction of NO synthase, it is obvious that proper NO synthase function is crucially dependent on BH4 supply. Inhibition of BH4 synthesis may, therefore, result in a quite selective suppression of inducible NO synthase activity. In line with this view are the results depicted in Figure 3 that demonstrate that the availability of BH4 is actually limiting the activity of NO synthase in IL-i /3-stimulated mesangial cells.
Comparable data have been reported in rat vascular smooth muscle cells [30] , in murine macrophages [42] , and in human umbilical vein endothelial cells [43] . Thus, it seems that in the presence of stimuli triggering the expression of inducible NO synthase, the enzyme is not saturated with BH4, although the cofactor's synthesis is enhanced in parallel [20] . In this context it is worth mentioning that cytokines and cAMP elevating agents synergize to trigger inducible NO synthase expression and nitrite production in mesangial cells [44, 45] to levels far beyond those achieved by IL-113 plus sepiapterin (Fig. 3) . These observation raise the possibility that synergistic induction of NO synthase activity by IL-1/3 and cAMP may depend, at least in part, on a combined effect not only on NO synthase expression, but also on the enzymatic pathway necessary for BH4 synthesis. This hypothesis is under evaluation in our laboratory. 
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